Ionis PharmaceuticalsLTS:0JDI +2.08%62 Gross Margin % is 98.78% as of Mar. 2026, which is 0% above its 10-year median of 98.54. GuruFocus rates LTS:0JDI with a GF Score™ of 62/100 and a GF Value™ of $53.57 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 736 Biotechnology companies, Ionis Pharmaceuticals ranks better than 95.79% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ionis Pharmaceuticals had a gross margin of 98.78% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ionis Pharmaceuticals Gross Margin % Related Terms
Ionis Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JDI vs EXEL, BBIO, AXSM: Gross Margin % Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ionis Pharmaceuticals (LTS:0JDI) has a Gross Margin % of 98.78% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Ionis Pharmaceuticals and its competitors. This is near median its historical median of 98.54. Over the past decade, Ionis Pharmaceuticals' Gross Margin % has ranged from 97.60 to 99.70. According to the industry distribution chart, Ionis Pharmaceuticals ranks #31 out of 736 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Ionis Pharmaceuticals' Gross Margin % too high?
Ionis Pharmaceuticals' current Gross Margin % of 98.78% is near median its 10-year median of 98.54. Over the past 10 years, this metric has ranged from a low of 97.60 to a high of 99.70. The Biotechnology industry median Gross Margin % is 60.91. Ionis Pharmaceuticals' value of 98.78% is 62.2% above this industry median. Based on the distribution chart, Ionis Pharmaceuticals ranks #31 out of 736 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ionis Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Gross Margin % compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #31 out of 736 companies for Gross Margin %. This places Ionis Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Ionis Pharmaceuticals' value of 98.78% is 62.2% above this benchmark. Historically, Ionis Pharmaceuticals' own Gross Margin % has ranged from 97.60 to 99.70 over the past decade. While the company's 10-year median is 98.54 vs. the industry median of 60.91, Ionis Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ionis Pharmaceuticals's current Gross Margin % of 98.78% is 62.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current Gross Margin % is 98.78%, which is near median its own 10-year median of 98.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.57, compared to a current price of $80.36 — trading 50% above its estimated fair value. The current Gross Margin % is 98.78%, which is near median its 10-year median of 98.54 and 62.2% above the Biotechnology industry median of 60.91. Ionis Pharmaceuticals' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Gross Margin % is 98.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of $80.36 is trading 50% above its estimated GF Value™ of $53.57.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for LTS:0JDI:
Gross Margin %: 98.78% (near median its 10-year median of 98.54)
GF Value™: $53.57 vs. price of $80.36 (50% above fair value)
Industry Position: 62.2% above the Biotechnology median (#31 of 736)
No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
62GF Score
Get the complete analysis for LTS:0JDI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDI has been successfully added to your 
